The Potential Benefits of S100B in Cardiac Surgery Brain Monitoring
In January 2022, researchers from d’Annunzio University (Neonatal Intensive Care Unit), Biago and C. Arrigo (Department of Maternal, Fetal, and Neonatal Medicine), Maastricht University (Department of Pediatrics and Neonatology), and IRCCS San Donato Milanese Hospital (Department of Pediatric Cardiac Surgery) discussed the use of protein S100B to predict short and long-term adverse neurological outcomes in adult and pediatric patients undergoing cardiac surgery. The complete manuscript by Giuseppe Lapergola, Alessandro Graziosi, Ebe D’Adamo, Patrizia Brindisino, Mariangela Ferrari, Anna Romanelli, Mariachiara Strozzi, Roberta Libener, Danilo A. W. Gavilanes, Antonio Maconi, Angela Satriano, Alessandro Varrica, and Diego Gazzolo is available in Clinical Chemistry and Laboratory Medicine. Detailed below is a summary of their article.
Congenital heart disease (CHD) accounts for 28% of all significant congenital anomalies and consists of malformations in the anatomy of the heart and/or great arteries during fetal development. Of those born with CHD, 30% are critical cases requiring surgical correction within the first year of life to prevent death. However, 50% of survivors suffer from neurocognitive developmental damage.